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Abstract
African Swine Fever Virus (ASFV) is a high-consequence transboundary animal pathogen
that often causes hemorrhagic disease in swine with a case fatality rate close to 100%. Lack
of treatment or vaccine for the disease makes it imperative that safe and efficacious vac-
cines are developed to safeguard the swine industry. In this study, we evaluated the immu-
nogenicity of seven adenovirus-vectored novel ASFV antigens, namely A151R, B119L,
B602L, EP402RΔPRR, B438L, K205R and A104R. Immunization of commercial swine
with a cocktail of the recombinant adenoviruses formulated in adjuvant primed strong ASFV
antigen-specific IgG responses that underwent rapid recall upon boost. Notably, most vacci-
nees mounted robust IgG responses against all the antigens in the cocktail. Most impor-
tantly and relevant to vaccine development, the induced antibodies recognized viral proteins
from Georgia 2007/1 ASFV-infected cells by IFA and by western blot analysis. The recom-
binant adenovirus cocktail also induced ASFV-specific IFN-γ-secreting cells that were
recalled upon boosting. Evaluation of local and systemic effects of the recombinant aden-
ovirus cocktail post-priming and post-boosting in the immunized animals showed that the
immunogen was well tolerated and no serious negative effects were observed. Taken
together, these outcomes showed that the adenovirus-vectored novel ASFV antigen cock-
tail was capable of safely inducing strong antibody and IFN-γ+ cell responses in commercial
swine. The data will be used for selection of antigens for inclusion in a multi-antigen proto-
type vaccine to be evaluated for protective efficacy.
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Introduction
The African Swine Fever Virus (ASFV) is a high-consequence Transboundary Animal Disease
(TAD) pathogen that causes hemorrhagic fever in swine and has mortality rates approaching
100% [1]. There is no vaccine or treatment available for this disease. The ASFV is a large envel-
oped double-stranded DNA icosahedral virus which exclusively infects the mammalian family
of suids and argasid ticks of the genus Ornithodoros. This pathogen is responsible for major
economic losses in endemic areas (sub-Saharan African countries and Sardinia) and poses a
high risk to swine production in non-affected areas as it continues to spread globally [2].
Therefore, it is imperative that appropriate counter-measures are developed to reduce the
prevalence of this disease in endemic areas, prevent further outbreaks in affected countries
and safeguard the swine industries in non-affected areas.
Development of an efficacious vaccine for ASFV is still a challenge. There is strong evidence
to suggest that protection against ASFV can be induced since attenuated virus has been shown
to protect against parental or closely related virulent isolates [3–5]. Attenuated vaccines, how-
ever, are yet to be rigorously tested in the field in readiness for deployment. Development of an
affordable DIVA (Differentiating Infected from Vaccinated Animals) ASFV subunit vaccine is a
more attractive option, especially for use in non-endemic areas, in case of an outbreak.
Subunit vaccines based on one or two ASFV antigens have so far failed to induce immunity
strong enough to confer significant protection among vaccinees [6–9], but, immunizing swine
with DNA plasmids expressing a library of restriction enzyme digested ASFV-genome frag-
ments conferred protection in a majority (60%) of the vaccinees against lethal challenge [10].
This result, though in favor of developing subunit based vaccines for ASFV, also highlights the
main challenges associated with it, i.e. identification of protective antigens as well as a suitable
delivery vector to induce strong protective responses. It is envisaged that successful develop-
ment of an effective subunit vaccine will require empirical identification and validation of
multiple suitable antigens that will induce significant protection in majority of the vaccinees.
We have previously shown that immunizing swine using a cocktail of replication deficient
adenoviruses expressing ASFV antigens p32, p54, pp62 and p72 elicited robust antigen-specific
antibody, IFN-γ+ cellular and cytotoxic T-lymphocyte (CTL) responses [11]. We used
E1-deleted/replication-defective human adenovirus (Ad5) vector since it is safe, gives high
protein expression levels and replicates at high titers in complementing cells making produc-
tion scalable and reproducible [12, 13]. In addition, efficacy of adenoviruses in swine immuni-
zations has previously been demonstrated in the successful development of a recently USDA-
licensed recombinant Foot and Mouth Disease vaccine [14, 15]. In this study, we evaluated
immunogenicity of seven ASFV vaccine candidates selected based on published literature
(Table 1).
The ability of these antigens to induce antibody and T-cell responses in commercial swine
has not been evaluated so far. The antigen, EP402R, has been previously evaluated, however,
only the extracellular domain was included and expressed as a fusion chimera along with other
ASFV antigens, p32 and p54. In this study, we altered the EP402R protein sequence to delete
the proline-rich repeats in the cytoplasmic tail and the resultant protein was designated
EP402RΔPRR. The proline-rich repeats have been shown to interact with the adaptor protein
SH3P7 in host cells and it is theorized that this interaction could, in part, be responsible for the
immunomodulatory role of the EP402R protein [27]. Thus, deletion of the proline-rich repeats
is expected to abrogate immunomodulatory effects when the EP402R protein is included in a
multi-antigen subunit vaccine.
The focus of this work was to evaluate the immunogenicity of seven novel ASFV antigens,
in commercial swine using replication-deficient adenovirus as a delivery platform with an end
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goal of identifying candidates for rationally designing a prototype multi-antigen ASFV subunit
vaccine.
Materials and methods
Generation of recombinant adenoviruses expressing ASFV antigens
The amino acid sequences of the ASFV antigens (Georgia 2007/1 isolate) were obtained from
Genbank (Accession FR682468). The EP402RΔPRR sequence was generated by deleting
the proline-rich repeats from the EP402R cytoplasmic domain [27]. Since K205R and A104R
polypeptides are short, they were fused in frame to generate a chimeric sequence, designated
K205R-A104R. The coding sequences of the target antigens (A151R, B119L, B602L, EP402RΔ
PRR, B438L, and K205R-A104R) were then modified to add, in-frame, a FLAG- and HA- tag
at the N- and C-termini, respectively, and the resultant amino acid sequences were used to
generate synthetic genes which were codon-optimized for protein expression in swine. Synthe-
sis, codon-optimization, cloning in pUC57 vector, and sequence-verification of these genes
was outsourced (GenScript, NJ, USA). Each target gene was then amplified by PCR using
attB1-FLAG specific forward and attB2-HA specific reverse primers and subcloned into Gate-
way pDonR221 vector (Invitrogen) as per manufacturer’s protocols. Positive pDonR clones
were validated by sequencing and used to transfer the gene cassette into the adenovirus back-
bone vector, pAd/CMV/V5-DEST (Invitrogen) by homologous recombination. Validated pos-
itive pAd clones were then used to generate recombinant adenoviruses, designated AdA151R,
AdB119L, AdB602L, AdEP402RΔPRR, AdB438L, and AdK205R-A104R, using the ViraPower
Adenoviral Expression System (Invitrogen). Antigen expression by the adenoviruses was con-
firmed by immunocytochemistry of infected Human Embryonic Kidney (HEK)-293A cells
(ATCC CRL-1573). One clone of each recombinant adenovirus was selected based on protein
expression and amplified in a T75 tissue culture flask to make a working stock. The working
stock was then used to infect up to 40 T175 flasks to generate bulk virus for immunization.
The infected cells were harvested, lysed by freeze-thawing three times and the lysate was recov-
ered. The titer of the virus in the cell lysates was determined by immunocytochemistry using
Table 1. Antigens selected for evaluation of immunogenicity.
Gene/
Antigen
Functional Characteristics /Immune Relevance Reference
A151R Essential for the virus replication and morphogenesis. May play a role in
viral transcription.
[16]
B119L Critical for virus assembly. 90% of deletion mutants are crippled and fail to
generate viable viral particles
[4], [17]
B602L Chaperone for p72 (major capsid protein), repression leads to decrease of
p72 expression, inhibition of pp220 and pp62 processing. Deletion
severely alters viral assembly. Recognized by domestic pig and bush pig
hyper-immune sera
[18], [19], [20],
[21].
EP402R ASFV Hemagglutinin. Extracellular domain contains protective T-cell
epitopes. Protective immunity against homologous infection maybe
haemadsorption inhibition (HAI) serotype-specific.
[22], [7], [23],
[24]
B438L Required for formation of vertices in icosahedral capsid [25]
K205R Induces strong antibody responses, but ability to elicit T-cell responses
has not been tested. Recognized by domestic pig and bush pig hyper-
immune sera
[20], [21]
A104R Histone-like protein. Primes strong antibody responses, mainly detected in
asymptomatic than chronically infected pigs. Presence of T-cell
determinants has not been evaluated.
[26], [21]
https://doi.org/10.1371/journal.pone.0177007.t001
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QuickTiter Adenovirus Titer Immunoassay kit (Cell Biolabs, Inc.) protocol with a slight modi-
fication as previously described [11]. Briefly, HEK-293A cells infected with serial dilutions of
the virus were first probed with rabbit anti-adenovirus polyclonal IgGs (1:500 dilution) (gener-
ated in-house), followed by an alkaline phosphatase-conjugated anti-rabbit IgG (1:1,000) (cata-
log number 711-055-152; Jackson Immuno-Research). FastRed TR/Naphthol AS-MX was
then used as the substrate (F4523; Sigma). The stained cells were counted (20X objective) and
the titer was calculated in IFU/ml. A recombinant adenovirus expressing luciferase, designated
Ad-Luc, was similarly prepared and served as a negative control immunogen.
Generation of recombinant ASFV antigens
The genes for antigens A151R, B602L, EP402RΔPRR, B438L, and K205R-A104R were PCR
amplified from the respective pDonR clones using FLAG-specific forward and HA-specific
reverse primers. The resultant PCR products were cloned into the pFastBac™ HBM TOPO
shuttle vector (Invitrogen). Positive clones were identified by PCR screening, sequence-veri-
fied and used to generate recombinant baculoviruses using the Bac-to-Bac HBM TOPO
Secreted Expression System (Invitrogen). Protein expression by the generated viruses was con-
firmed by immunocytochemistry of infected Sf-9 cells. One clone of each baculovirus was then
scaled up and used to infect High Five cells (Invitrogen) to generate recombinant proteins.
These proteins were affinity-purified using the anti-FLAG M2 affinity gel (Sigma, A2220).
Recombinant B119L was affinity purified similarly, but from AdB119L-infected HEK-293A
cell lysates.
Validation of protein expression
Immunocytochemistry. Protein expression by the recombinant adenoviruses was evalu-
ated by immunocytochemistry as described previously [28]. Briefly, HEK-293A cell monolay-
ers infected with the recombinant adenoviruses, were probed with mouse anti-HA–alkaline
phosphatase conjugate (Sigma, St. Louis, MO) diluted 1: 1,000 in Blocking buffer (PBS with
5% fetal bovine serum). Duplicate infected HEK-293A cell monolayers were first incubated
with a gamma-irradiated convalescent swine serum (1:250 dilution)[11]. Following 3X washes,
the cells were further incubated with a 1:500 dilution of alkaline phosphatase-conjugated goat
anti-porcine IgG (Southern Biotech, Cat# 6050–04) for 1 hr. Following washes as above, Fast
Red TR–Naphthol AS-MX substrate (Sigma, F4523) was added to the cells to detect the alka-
line-phosphatase activity. Protein expression by the recombinant baculoviruses was similarly
evaluated by infecting Sf-9 cells. Mock infected cells served as negative controls.
Western blot. Affinity-purified recombinant proteins (A151R, B119L, B602L, EP402RΔ
PRR, B438L, and K205R-A104R) were resolved by SDS-PAGE and transferred to Immobolin-
P PVDF Membrane (Fisher Scientific). Following an overnight incubation at 4˚C with block-
ing buffer (10% non-fat dry milk TBST), the membrane was incubated with ASFV-specific
convalescent serum (1: 2,500 dilution in blocking buffer) for 1hr. The membrane was then
washed 3X with TBST and incubated with peroxidase-conjugated Goat anti-swine IgG
(1:5,000) (Jackson ImmunoResearch, Cat #114-035-003). Chemiluminescence was detected
by the SuperSignal West Pico PLUS substrate (Thermo Scientific, Prod #34577).
Swine immunizations. Twenty weaned swine were randomly distributed into the treat-
ment and control groups (n = 10). The treatment group was immunized with the Ad-ASFV
cocktail (1 X 1011 IFU) of each construct (formulated in ENABL adjuvant (Benchmark Biolabs,
Cat# 7010106-C6)). The control group received Ad-Luc (6 x 1011 IFU) formulated as above.
The inoculum (5ml) was injected intramuscularly (1-2ml/site) in the neck area behind the
ears. The animals were then boosted similarly after 8 weeks. Blood was collected for sera and
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PBMC isolation once pre-immunization and then biweekly post-prime, and then weekly post-
boost for 3 weeks to run ELISAs and IFN-γ ELISPOTs. The animals were euthanized at 4
weeks post-boost.
ELISA
Antigen-specific antibody responses were evaluated by an indirect ELISA as previously
described [11]. Briefly, microplates coated overnight at 4˚C with 100 μl of 1 μg/ml of affinity-
purified antigen in bicarbonate coating buffer were washed and blocked with 10% non-fat dry
milk in PBS with 0.1% Tween 20 for 1 hr. Sera were diluted at 1:100 (week 4 post-prime) or
1:8,000 (week 2 post-boost) in blocking buffer and added at 100 μl per well in triplicates. After
incubation for 1 hr. at 37˚C, the plates were washed and incubated for another hr. with 100 μl/
well of a 1: 5,000 dilution of peroxidase-conjugated anti-swine IgG (Jackson ImmunoResearch,
Cat# 114-035-003). Following washes, the plates were developed with Sure Blue Reserve TMB
substrate (KPL, Cat# 53-00-02) and reaction was stopped using 1N Hydrochloric acid. The
absorbance at 450 nm was read using BioTek microplate reader (Synergy H1 Multi-mode
reader). The IgG response by each animal to each antigen was calculated as mean absorbance
of test sera minus the mean absorbance of the cognate pre-immunization sera. To determine
antigen-specific IgG end-point titers, sera from blood collected two weeks post-boost was seri-
ally diluted two-fold starting at 1: 4,000 up to 1: 4 X 106. The pre-immunization serum was
similarly diluted. The end-point titer was calculated as described previously [11].
Indirect Fluorescence Antibody assay (IFA)
Pretreated Teflon coated slides with fixed ASFV (Georgia 2007/1)-infected and mock-infected
VERO cells (ATCC CCL-81) were used to perform the IFA as previously described [11].
Briefly, the slides were incubated with sera from two weeks post-boost diluted 1:250 for 1 hr. at
37˚C. ASFV-specific convalescent serum (1: 10,000) was used as a positive control and normal
swine serum (1:250) (GIBCO) was used as a negative control. Following extensive washes with
D-PBS, the wells were incubated with FITC-conjugated goat anti-swine sera (Kirkegaard and
Perry Cat No. 02-14-02) for 45 minutes at 37˚C, washed again and mounted with Prolong
Gold antifade reagent with DAPI (Invitrogen, Cat. No. PT389868). The cells were visualized at
a 40X magnification using an Olympus immuno-fluorescent microscope (model BX-40) and
photographed by an Olympus digital camera (model DP 70). The IFAs were conducted at
Plum Island Animal Disease Center.
Western blot with ASFV-infected cell lysates
Lysates from ASFV Georgia 2007/1 (VERO cell-adapted)-infected VERO cells were used to
perform a western blot as previously described [11]. Briefly, the prepared cell lysates were elec-
trophoresed on a NuPAGE 4–12% Bis-Tris Gel (1.0mm X 2D well) for 35 mins, followed by
transfer to 0.2 μm PVDF membranes (Invitrogen #LC2002) for 1 hour. The membranes were
then blocked for 1 hr. in blocking buffer (PBST+5% non-fat dry milk) and transferred to the
Protean II Slot-Blotter. Sera from week 2 post-boost were diluted 1:250 in blocking buffer and
added to individual wells for 1 hr. at room temperature with shaking. After washing the wells
3X with PBST, the membranes were removed from the blotting apparatus and incubated for 1
hr. with a 1: 2,000 dilution of Goat anti-swine-HRP (KPL #14-14-06). Following washes, the
membranes were developed using DAB (Sigma #D4293). ASFV-specific convalescent serum
(1:10,000) was used as a positive control and normal swine serum (1:200) was used as a negative
control. Background reactivity to host-cell antigens was gauged similarly using mock-infected
lysates. The western blot analysis was carried out at Plum Island Animal Disease Center.
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IFN-γ ELISPOT assays
Antigen-specific IFN-γ+ cell response was evaluated by an enzyme-linked immunospot (ELI-
SPOT) assay using the Mabtech kit (Cat# 3130-2A), as per manufacturer’s instructions and
as previously described [11]. Briefly, whole blood-derived PBMCs resuspended in complete
RPMI-1640 media were added to wells of MultiScreen-HA plates (Millipore) at a density of
250,000 cells/well. Affinity-purified antigens were added to the cells at a final concentration of
2.5 μg/ml in triplicates. Phytohemagglutinin (PHA) mitogen (5 μg/ml) was used as a positive
control, whereas media served as the negative control. The spots were counted by an ELISPOT
reader and AID software (AutoImmun Diagnostica V3.4, Strassberg, Germany). The mean
number of IFN-γ+ Spot-Forming Cells (SFC) for each sample was calculated by subtracting the
mean number of spots in the negative control wells from the mean number of spots in the
sample wells. The data is presented as mean number of SFC per 106 PBMCs.
Statistical analysis
The differences in the mean antigen-specific antibody and IFN-γ+ responses between the treat-
ment and the control group were analyzed by an unpaired t-test with Welch’s correction, and
a P value of0.05 was considered significant. The analysis was performed with GraphPad
Prism Version 6.05 using a significance level of P<0.05.
Ethics statement
All animal procedures were conducted as per the Animal Use Protocol 2014–0020, reviewed
and approved by the Texas A&M University Institutional Animal Care and Use Committee
(IACUC). The Texas A&M IACUC follows the regulations, policies and guidelines outlined in
the Animal Welfare Act (AWA), USDA Animal Care Resource Guide and the PHS Policy on
Humane Care and Use of Laboratory Animals. The animals were monitored twice daily for
any clinical signs and to document any localized and or systemic adverse effects. At the termi-
nation of the study, the animals were euthanized with an overdose of sodium pentobarbital.
Results and discussion
Recombinant constructs encoding ASFV antigens
Codon-optimized synthetic genes encoding antigens, A151R, B119L, B602L, EP402RΔPRR,
B438L, and K205R-A104R fused in-frame to FLAG and HA tags were used to generate recom-
binant adenoviruses designated AdA151R, AdB119L, AdB602L, AdEP402RΔPRR, AdB438L,
and AdK205R-A104R. The immunogenicity of K205R and A104R was evaluated as a chimera
since both proteins are relatively small (~20kDa and ~10kDa) and delivering them in vivo as a
chimera would reduce the number of adenoviruses to be inoculated. Evaluation of protein
expression by immunocytochemistry of adenovirus-infected HEK-293A cells using anti-HA
mAb and the ASFV-specific convalescent serum showed that the assembled recombinant ade-
noviruses expressed full-length authentic ASFV antigens (Fig 1A and 1B). The synthetic ASFV
genes were also used to generate recombinant baculoviruses for generation of affinity-purified
recombinant proteins needed for in vitro evaluation of antigen-specific antibody and cell
responses. However, despite several attempts, we were unsuccessful in generating a recombi-
nant baculovirus expressing B119L and thus we used affinity-purified antigen from AdB119L-
infected HEK-293A cells for in-vitro readouts. The authenticity of the affinity-purified recom-
binant proteins was validated by western blot using ASF-specific convalescent serum (Fig 1C).
Strong bands were detected for all antigens except B438L. The predicted molecular weight of
B438L (with the FLAG and HA tags) is ~56kDa. A very faint diffused band (depicted by an
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arrow) slightly lower than 75 kDa was observed for antigen B438L. The antigen loads had been
optimized for signal detection, however, for antigen B438L a strong signal was not detected
despite increasing antigen load to microgram quantities (see S1 Fig). This could be a result of
low B438L-specific antibodies in the ASFV-specific convalescent serum. To confirm this
observation, we performed western blots of antigens A151R (as a positive control) and B438L,
probed with either an anti-HA mAb or the ASFV-specific convalescent serum (S2 Fig). The
band at slightly <75kDa was detected with the anti-HA mAb for antigen B438L, however, no
signal was seen with the convalescent serum. This validates that the absence of a strong signal
for B438L in the western blot in Fig 1C was indeed due to low B438L-specific antibodies (also
confirmed by an ELISA discussed later in the manuscript) in the serum and not an insufficient
antigen load.
Ad5-ASFV cocktail primed ASFV antigen-specific antibodies
Twenty commercial swine were randomly divided into two groups (n = 10). Animals of the
treatment group were immunized with a cocktail of six recombinant adenoviruses expressing
the A151R, B119L, B602L, EP402RΔPRR, B438L, and K205R-A104R ASFV antigens, whereas
the negative control group received Ad-Luc sham treatment. After priming, antigen-specific
IgG responses were detected in a majority of swine in the treatment group, but not the control
Fig 1. Protein expression by ASFV constructs. The expression and authenticity of the ASFV antigens encoded by the generated recombinant
constructs was evaluated by immunocytochemistry and western blot analysis. Panels: A) HEK-293A cells infected with recombinant adenoviruses
and probed with anti-HA mAb; and B) HEK-293A cells infected with recombinant adenoviruses and probed with gamma-irradiated ASFV-specific
convalescent serum. Negative controls are mock infected HEK-293A cells. C) A western blot of the affinity purified ASFV proteins probed with the
convalescent serum. The molecular weights are expressed in kDa. The arrow points to the faint band detected for B438L (the signal intensity of the band
increased with longer exposure times).
https://doi.org/10.1371/journal.pone.0177007.g001
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group. Data from sera analyzed four weeks post-priming is shown (Fig 2A). The mean re-
sponse of the treatment group was significantly higher than the control group for antigens
A151R (p<0.001), B119L (p<0.01), B602L (p<0.001), B438L (p<0.05) and K205R-A104R
(p<0.001). The mean antibody response against the EP402RΔPRR antigen by the swine in the
treatment group was slightly higher than the controls but not significant. The strong mean
responses observed against antigens B602L and K205R-A104R is consistent with previous
studies where these antigens have been shown to be strongly recognized by domestic pig and
bush pig hyper-immune sera [20, 21]. Following boosting at 8 weeks post-priming, antigen-
specific recall IgG responses against all antigens were detected in the animals in the treatment
group (Fig 2B). The mean response of the treatment group was significantly higher than the
control group for antigens A151R (p<0.01), B119L (p<0.001), B602L (p<0.05), EP402RΔPRR
(p<0.05), and K205R-A104R (p<0.01), but not for antigen B438L. It is important to note
that the responses at week 2 post-boost were evaluated at 1:8,000 sera dilution, whereas the
responses post-prime were evaluated at a 1:100 sera dilution (Fig 2). This eliminated the back-
ground responses observed against some antigens post-prime in the control group. However,
for antigen B119L, the control group still had a low-level of background reactivity after boost-
ing. This background response could be attributed to vector and host-cell line (HEK-293A)-
specific antibodies since the affinity-purified B119L antigen was derived from lysates of
AdB119L-infected HEK-293A cells. Also the response seen in the treatment group is also likely
to be inclusive of a low level of vector and host-cell line specific antibodies. Evaluation of anti-
gen-specific end-point titers post-boost in the immunized pigs showed that a majority of the
vaccinees had titers 1:256 x 103 against antigens A151R, B119L, B602L, and K205R-A104R
(Fig 3). The highest titer was 1:2 x 106 against B602L in one of the vaccinees (Fig 3). A compar-
ison of the antigen-specific titers in sera from the vaccinees with the titer of the ASFV-specific
convalescent serum revealed that Ad-ASFV cocktail was able to induce titers higher or equiva-
lent to the convalescent serum in a majority of animals for antigens B119L (90% of vaccinees),
B438L (90% of vaccinees), B602L (80% of vaccinees), and EP402RΔPRR (80% of vaccinees).
This is a noteworthy result, since these animals received only two immunizations of the Ad-
ASFV cocktail, whereas the positive control convalescent serum came from an animal that
received multiple inoculations of live ASFV [11]. However, for antigen, K205R-A104R only 3
Fig 2. Mean antigen-specific IgG responses post-priming and post-boost. Antigen-specific IgG
response was evaluated post-prime and post-boost by ELISA. A) Sera from week 4 post-prime were
evaluated at a 1:100 dilution. B) Sera from week 2 post-boost were evaluated at a 1:8,000 dilution (to prevent
the absorbance values from going out of range). The error bars represent the SEM. The asterisks denote a
significant difference between the mean response of the treatment and control animals. *p<0.05, **p<0.01,
***p<0.001.
https://doi.org/10.1371/journal.pone.0177007.g002
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of 10 vaccinees had titers that matched up to the convalescent serum, whereas for antigen,
A151R the titers induced in the vaccinees did not match up to the convalescent serum.
The role of antibodies in ASFV protection is not yet completely understood, however
strong evidence in favor of antibodies (reviewed in [29]) and importantly, protection reported
by passively acquired anti-ASFV antibodies supports the evaluation of humoral responses
in immunogenicity studies focused on identification of novel targets for subunit vaccine de-
velopment [30, 31]. In the current study, a cocktail of replication-incompetent adenovirus
constructs expressing multiple ASFV antigens primed strong antibody responses against all
antigens in a majority of the animals.
Antibodies triggered by the Ad5-ASFV cocktail recognized ASF virus
Indirect Immunofluorescence Antibody Assay (IFA) performed with sera from blood collected
from the vaccinees two weeks post-boost, confirmed that the antibodies triggered by the
Ad5-ASFV cocktail recognized VERO cells infected with the actual ASF virus (Georgia 2007/1
Fig 3. Antigen-specific end-point IgG titers. Antigen specific antibody titers, determined by ELISA, in sera
from treatment group animals (T) collected two weeks post-boost. The dilution of the sera at which the
absorbance reading was higher than that of the cognate pre-bleed +3 standard deviations is reported as the
end-point titer. The ASFV-specific convalescent serum was titrated similarly and is represented by the red star
symbol (S). Data is represented as the reciprocal of the end-point sera dilution x 106. For antigen, B119L the
sera from control group animals was also titrated to gauge background reactivity to host-cell and vector-
derived antigens. An average of the titers of the control group animals was then subtracted from the titer of
each treatment group animal to give B119L-specific titers. For the remaining antigens, the post-boost sera
from the control group animals showed no reactivity as seen in Fig 2B.
https://doi.org/10.1371/journal.pone.0177007.g003
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isolate) but not mock-infected cells (Fig 4A). Sera from 8 out of 10 swine in the treatment
group, but none from the controls, recognized the ASFV-infected cells (Table 2). Sera from 2
animals (swine 89 and swine 91) were most reactive and reacted with the plasma membrane, a
virus–factory like structure and general cytoplasm. Western blot analysis of ASFV-infected
Vero cell lysates probed with the post-boost sera also validated the above results (Fig 4B). This
outcome showed that synthetic genes encoding antigens of ASFV (a Risk Group 3 pathogen)
that requires BSL3 biocontainment can safely be used at BSL2 level to develop and test immu-
nogenicity and tolerability of prototype ASFV vaccines. These results, however do not directly
demonstrate that the ASFV-specific antibodies have functional activity. In case of ASFV, it is
generally acceptable in the scientific community, that conventional plaque reduction assay to
measure ASFV antibody neutralization activity is technically difficult since low-passage (viru-
lent) ASFV strains show no or a significant delay in plaque formation, and is especially difficult
to conduct the assay in primary swine macrophage cells. A highly attenuated ASFV Georgia
strain that is adapted to a suitable cell line (e.g., VERO cells), or a genetically modified ASF
virus expressing a chromogenic marker gene, for use in testing study samples for virus neutral-
ization activity was not available at the time the study was conducted.
Ad5-ASFV cocktail primed IFN-γ-secreting cells
Low frequencies of antigen-specific IFN-γ responses were detected in a few animals by IFN-γ
ELISPOT analysis of PBMCs collected one-week post-priming (Fig 5A). Specifically, a signifi-
cant difference (p<0.05) between the mean response of the treatment group and negative con-
trol group animals was detected only for antigen A151R (Fig 5A). However, after boosting,
strong recall IFN-γ+ responses were detected in a majority of animals for all the antigens (Fig
5B). The mean response of the treatment group was significantly higher than the control
group for all antigens (p<0.05 for antigens B119L, B602L, EP402RΔPRR, and p<0.01 for anti-
gens A151R, B438L, and K205R-A104R). The IFN-γ ELISPOT data clearly showed that the
homologous booster dose was able to sufficiently amplify the primary response to give strong
recall responses against all antigens in a majority of the vaccinees (Fig 5). The high frequencies
of antigen-specific IFN-γ+ cellular responses induced are promising in light of the results
reported from other subunit vaccine studies. Notably, immunization with an ubiquitin tagged
chimera of antigens p30, p54 and CD2v using DNA plasmids conferred protection against
lethal challenge in some of the vaccinees [7]. In addition, in another study, by the same
authors, immunizing animals with BacMams expressing the same antigen chimera (p30, p54
and CD2V) conferred partial protection upon a sub-lethal challenge, and a direct correlation
between protection and ASFV-specific IFN-γ+ response was observed [6]. Interestingly, in
both studies the IFN-γ response against the extracellular domain of EP402R was negligible.
We have shown that the adenovirus-vectored EP402RΔPRR induced strong antigen-specific
IFN-γ+ responses in 70% of the vaccinees post-boost.
Ad5-ASFV cocktail was well tolerated
Following inoculation of the Ad-ASFV cocktail, three swine in the treatment group were
observed to be depressed and one had mild fever on the first day. However, all the swine were
normal on all subsequent days. After boosting, one pig in the treatment group was observed to
be depressed and had fever that required treatment with Banamine. All the swine in the nega-
tive control group were normal post-priming and post-boosting. Overall, the Ad-ASFV cock-
tail was well tolerated with no adverse effects.
The overall outcome is evidence that a vaccine formulated using a cocktail of replication-
incompetent adenovirus expressing protective ASFV antigens is likely to be well tolerated by
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Fig 4. Antibodies primed by the Ad-ASFV cocktail recognized ASF virus. Analysis of sera from two weeks post-boost by Indirect
Fluorescence Antibody assay (IFA) and western blot showed that the antibodies primed by the Ad-ASFV cocktail recognized the parental ASFV
infected cells and ASFV-derived antigens. Panel A) Vero cells infected with ASFV Georgia 2007/1 probed with sera from treatment and negative
control animals. ASFV specific convalescent serum was used as the positive control and normal swine serum served as the negative control. Data
for three animals (that gave the strongest reaction) from the treatment group and one animal from the control group is shown. A summary of IFA
results for all animals is presented in Table 2. B) Lysates from Vero cells infected with ASFV Georgia 2007/1 isolate were blotted and probed with
sera from all animals. Normal swine serum was the negative control and ASFV-specific convalescent serum was the positive control. Differences
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commercial swine at doses as high as 1011 IFU used in a homologous prime-boost immuniza-
tion regimen. This scenario is anticipated since effective ASFV subunit vaccines will likely
require delivery of multiple antigens given that studies conducted so far have shown that a
combination of one or a few antigens does not confer complete protection.
Conclusion
The African Swine Fever Virus (ASFV) continues to pose a high risk to the swine industry
and it is still causing economic losses in endemic areas. Since there is no vaccine or treatment
available yet, it is important to identify viral proteins that can elicit strong immune responses
and therefore be considered viable candidates for subunit vaccine development. We have
optimized an adenovirus-vector based ASFV antigen delivery system which allows for immu-
nization of swine with multiple ASFV antigens and the subsequent evaluation of their immu-
nogenicity. The robust antigen-specific IFN-γ+ responses induced by the adenovirus vector
against all the antigens tested in this study as well as other ASFV antigens evaluated in our
previous study make it a promising delivery platform for testing vaccine candidates for protec-
tion against ASFV [11]. Upon investigation of antigen-specific responses of individual ani-
mals, we observed a significant (p<0.05) positive correlation between the antigen-specific
IFN-γ response and the antigen-specific end-point antibody titers for 4 of the 6 antigens (see
S3 Fig). An interesting observation, in regards to antigen B438L, is the relatively low humoral
responses in contrast to the strong IFN-γ+ responses induced (Fig 3, Fig 5, S3 Fig). The inabil-
ity of this antigen to induce strong antibody responses was corroborated by the fact that the
ASFV-specific convalescent serum also had a comparatively low B438L-specific titer (1:4,000).
Thus, even though B438L does not induce a high antibody response, it still is an attractive
in coloration are due to actual band intensities; darker color is higher concentration of antibody bound to antigen (antigen concentration is
constant).
https://doi.org/10.1371/journal.pone.0177007.g004
Table 2. Summary of IFA results.
Treatment
Group:
Swine No.
Reactivity Control
Group:
Swine No.
Reactivity
ASFV-infected
Vero cells
Mock-infected
Vero cells
ASFV-infected
Vero cells
Mock-infected
Vero cells
76 +++ - 77 - -
78 - - 79 - -
81 ++ - 80 - -
82 +++ - 84 - -
83 - - 85 - -
89 +++ - 87 - -
90 + - 88 - -
91 ++++ - 93 - -
92 + - 95 - -
96 +++ - 99 - -
ASFV convalescent serum ++++ - Normal serum - -
The number of ‘+’ signs represents the comparison between the intensity of a positive signal from the sera of the animals and that from the ASFV-specific
convalescent serum (positive control).
‘++++’: signal as strong as positive control
‘+’: weakest but positive signal
‘-‘: No signal detected
https://doi.org/10.1371/journal.pone.0177007.t002
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Fig 5. ASFV antigen-specific IFN-γ response post-prime and post-boost. The frequency of antigen-
specific IFN-γ-secreting cells in PBMCs collected post-prime and post-boost was evaluated by IFN-γ
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candidate for future efficacy studies based on its ability to induce strong IFN-γ+ cell responses.
This study also showed that an adenovirus-based ASFV vaccine can be used successfully for
homologous prime-boost vaccination. If this approach is shown to confer protection, it will
cut costs incurred by use of a heterologous prime-boost immunization strategy. Thus, these
findings support use of the replication-incompetent adenovirus as a vector for the develop-
ment of a commercial vaccine for protection of pigs against African swine fever virus. The
next logical step is to test whether these multiple ASFV antigens delivered in a cocktail format
can confer protection in a challenge study.
Supporting information
S1 Fig. SDS-PAGE of affinity purified ASFV antigens. Coomassie (Thermo Scientific Impe-
rial Protein Stain) stained gel of affinity-purified recombinant ASFV proteins. The protein
load for each of the antigens was 1μg based on BCA assay. The affinity-purified preps for anti-
gens B119L and B438L contain other contaminating proteins. For antigen B119L, the band
detected on the western (~40 kDa) (Fig 1C) is faint but visible on the stained gel. For antigen
B438L, the arrow points to the faint band detected on the western blot (Fig 1C). The amount
of sample loaded for the western blot was 0.1 to 1X the amount on the stained gel (to achieve
optimal band intensity when probed with the convalescent sera) for all antigens except B438L.
For antigen B438L, the amount loaded on the western blot (in Fig 1C) was increased to 8X
(8 μg) the amount on the stained gel, to enable detection of the faint band.
(PDF)
S2 Fig. SDS PAGE and western blots of antigen B438L. A) Coomassie (Thermo Scientific
Imperial Protein Stain) stained gel of affinity-purified recombinant ASFV proteins, A151R
(used as a control) and B438L; B) Western blot of proteins A151R and B438L probed with
anti-HA mAb; and C) Duplicate western blot probed with ASFV-specific convalescent serum.
The protein load for both antigens on the western blots is 0.1X the load on the PAGE.
(PDF)
S3 Fig. Antigen-specific correlation between IFN-γ and antibody response. Correlation
analysis of antigen-specific IFN-γ and antibody titers of individual animals revealed a signifi-
cant (p<0.05) positive correlation for all antigens except EP402RΔPRR and B438L. The Pear-
son correlation coefficient (r) and the statistical significance for each correlation is shown. 
represents p<0.001,  represents p<0.01,  represents p<0.05 and ‘ns’ stands for a non-signif-
icant difference.
(PDF)
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